SHL partner Innovation Zed announces plans to launch InsulCheck DOSE

InsulCheck DOSE by Innovation Zed is designed and developed in collaboration with SHL Medical

SHL Medical and Innovation Zed have announced plans to launch InsulCheck® DOSE in 2022.

InsulCheck DOSE by Innovation Zed is a reusable add-on device that uses Bluetooth® technology to automatically transfer injection time and number of dose units dialed to a mobile application. It features an OLED display that counts up the time elapsed since last injection, shows the last dose unit, as well as indicates mounting/unmounting activities. Data from the device can be sent to a third-party software application for automated logging of injection information. It is designed and developed in collaboration with SHL Medical.

“Innovation Zed’s InsulCheck DOSE will become an integral part of SHL Medical’s digital healthcare ecosystem, which combines our initiatives in connected drug delivery technologies with our digital health program. A flexible digital ecosystem is key to providing value to patients in a rapidly changing environment. The collaboration between Innovation Zed and SHL demonstrates the versatility of SHL’s growing digital ecosystem for connected drug delivery devices. We are extremely excited about the launch and the added value it can bring to pharma, clinicians, patients and other stakeholders,” said Nils Weber, Global Head of Emerging Technologies and Digital Health at SHL Medical.

InsulCheck DOSE is the third-generation product from Innovation Zed’s InsulCheck family, which includes InsulCheck CLASSIC and InsulCheck CONNECT. Core to the InsulCheck technology is a prominent screen indicating the device’s status and the time since last injection. A customizable sleeve allows the InsulCheck devices to accommodate a variety of pen-based injection treatments.[2] At launch, InsulCheck DOSE will support a range of reusable and disposable insulin injection pens on the market.[1]

InsulCheck DOSE also features a built-in firmware with algorithms unique to compatible pens. Its proprietary multi-sensor technology enables high-accuracy detection of units dialed. A built-in firmware over-the-air (FOTA) capability allows continuous optimization of the device’s firmware even when deployed in the field. This futureproofing feature will allow InsulCheck DOSE to update its algorithms and improve on device performance.

“We have taken a unique approach in developing this technology by working closely with users, caregivers, software developers, medical device specialists and previous generations of InsulCheck products to design and develop a product that bolsters and supports the needs of all stakeholders,” said Dr. Dean Minnock, CEO at Innovation Zed. “Through automated logging, we enable patients to turn their traditional injection pen into a smart pen and provide them with easier access to their injection data.”

InsulCheck DOSE is expected to enter production at the end of Q2 2022. Manufacturing of InsulCheck DOSE will be handled by SHL Technologies, a subsidiary of SHL Medical. For more information on the device features and specifications, please refer to the full press release from Innovation Zed.



References

• Innovation Zed. (2021). Innovation Zed Announce 2022 Launch of InsulCheck DOSE Add-on Technology for Insulin Pens.
• Innovation Zed. Products. InsulCheck. Retrieved November 24, 2021.